Relating protease inhibitor resistance at time of virological failure with drug exposure

Background: The absence of detectable HIV resistance after treatment failure may result from non-adherence, especially for drugs such as ritonavir-boosted PIs (PI/r) for which minimum adherence may be sufficient to achieve suppression. This analysis aimed to investigate the association between adherence, indicated by a detectable PI plasma concentration, and development of PI resistance in patients presenting with virological failure of a PI/r regimen. Supplement: Abstracts of the Tenth International Congress on Drug Therapy in HIV Infection http://www.biomedcentral.com/content/pdf/1758-2652-13-S4-info.pdf Conference: Tenth International Congress on Drug Therapy in HIV Infection 7-11 November 2010 Glasgow, UK (Published: 8 November 2010) doi:10.1186/1758-2652-13-S4-P118 Cite this article as: Van Luin et al.: Relating protease inhibitor resistance at time of virological failure with drug exposure. Journal of the International AIDS Society 2010 13(Suppl 4):P118. Full text: PubMed Central: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112893/